New PCa Screening Algorithm Proposed

Investigators have proposed a new approach to prostate cancer (PCa) screening in which a PSA level of 1.5 ng/mL or higher should prompt referral to a urologist for further evaluation.

Dementia Linked to Prostate Cancer ADT

Androgen deprivation therapy (ADT) for prostate cancer (PCa) is associated with an increased risk of dementia, according to a new study.

HIPAA: Protecting Computers From Hacking

Medical practices can take a number of steps either on their own or with the help of IT firms to make it more difficult to hack into a practice's computer files.

Dietary Potassium Doesn't Up Hyperkalemia

Increases in dietary potassium over a 4-week period do not cause hyperkalemia in hypertensive patients with normal renal function who are receiving ACE inhibitor or angiotensin receptor blocker (ARB) therapy, new findings suggest.

PCa Progression Risk Lower With Degarelix

Patients with metastatic or high-risk prostate cancer (PCa) treated with degarelix have improved PSA progression-free survival compared with those treated with luteinizing hormone-releasing hormone (LHRH) antagonists, investigators reported at the European Society for Medical Oncology 2016 congress in Copenhagen.

Benchmarking Essentials

With healthcare payers' focus on patient satisfaction and move toward pay for performance, it is imperative to know where your practice stands.

PCa Active Surveillance High in Sweden

Sweden leads the United States and other nations in the use of active surveillance (AS) for low-risk prostate cancer (PCa), new findings suggest.

Cabozantinib as Front-Line Therapy for RCC

Cabozantinib is superior to sunitinib as first-line treatment of previously untreated patients with intermediate- or poor-risk advanced renal cell carcinoma (RCC), investigators reported at the European Society for Medical Oncology 2016 congress in Copenhagen.

Extracorporeal Therapy for Poisoning

A workgroup has developed guidelines for the use of hemodialysis treatments for common toxicities.

AKI From Radiocontrast May Be Overestimated

Clinicians may be overestimating the risk of nephropathy associated with radiocontrast administration, according to a study.

CME: SGLT-2 Inhibitors for Type 2 ...

Increased clinical research has been focused on the sodium-glucose co-transporter 2 (SGLT-2) inhibitors for the management of type 2 diabetes.

Looking for a Job?

Access our job board to view over 1,000 job openings throughout the US.

RUN Social Media Survey

Tell us about your social media habits for a chance to win a free gift card.

Sign Up for Free e-newsletters